Cargando…

Correction: PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915283/ https://www.ncbi.nlm.nih.gov/pubmed/35273102 http://dx.doi.org/10.1136/jitc-2021-002500corr1

Ejemplares similares

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
por: Shi, Xiaojuan, et al.
Publicado: (2019)

Correction: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
Publicado: (2023)

A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
por: Xu, Da-Lai, et al.
Publicado: (2022)

Correction: Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Publicado: (2022)

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Correction: Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8(+)CD11c(+) PD-1(lo) Effector T Cells
por: Goudin, Nicolas, et al.
Publicado: (2017)

Tuft Cells: Detectors, Amplifiers, Effectors and Targets in Parasite Infection
por: Campillo Poveda, Marta, et al.
Publicado: (2023)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

Correction: The Kinematics of Cytotoxic Lymphocytes Influence Their Ability to Kill Target Cells
Publicado: (2014)

Correction to ‘The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy’
por: Kimmel, Gregory J., et al.
Publicado: (2022)

Correction: PlexinD1 Is a Novel Transcriptional Target and Effector of Notch Signaling in Cancer Cells
Publicado: (2016)

Correction to: Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
por: Wen, Liling, et al.
Publicado: (2022)

Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
por: Voigt, Emily A., et al.
Publicado: (2022)

Correction: Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
Publicado: (2023)

Correction: A New Recombinant BCG Vaccine Induces Specific Th17 and Th1 Effector Cells with Higher Protective Efficacy against Tuberculosis
Publicado: (2014)

Correction: HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
por: Ma, Juan, et al.
Publicado: (2013)

Targeting PD-L1 in non-small cell lung cancer using CAR T cells
por: Liu, Ming, et al.
Publicado: (2020)

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers
por: Chinsuwan, Thanyavi, et al.
Publicado: (2023)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Correction to: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
por: Śledź, Marta, et al.
Publicado: (2023)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

Correction: Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
Publicado: (2020)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden
por: Femel, Julia, et al.
Publicado: (2022)

Correction to: Moralization and extremism robustly amplify myside sharing
Publicado: (2023)

Correction to: Moralization and extremism robustly amplify myside sharing
Publicado: (2023)

Correction: PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing
por: Akhmetzyanova, Ilseyar, et al.
Publicado: (2015)

Correction: Robust CAR-T memory formation and function via hematopoietic stem cell delivery
por: Zhen, Anjie, et al.
Publicado: (2021)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

Correction: Withania somnifera Root Extract Has Potent Cytotoxic Effect against Human Malignant Melanoma Cells
por: Halder, Babli, et al.
Publicado: (2015)

Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
por: Trinschek, Bettina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b5igu0jk3smt8o8dvpsv370hlj